TG Therapeutics (TGTX) Is Up 7.6% After Advancing Subcutaneous BRIUMVI Phase 3 Trial Enrollment Completion TG Therapeutics, Inc. TGTX | 36.62 | -0.81% | - TG Therapeutics recently completed enrollment in a Phase 3 trial of a subcutaneous formulation of BRIUMVI for adults with relapsing multiple sclerosis, comparing every 8- and 12-week dosing to the currently approved intravenous regimen on pharmacokinetics, safety, and clinical outcomes. - A key focus of the study is whether subcutaneous BRIUMVI can match the drug exposure of the intravenous form while potentially offering a more convenient administration schedule and expanding its clinical utility. - Against this backdrop, we'll examine how advancing a potentially more convenient subcutaneous BRIUMVI formulation could reshape TG Therapeutics' investment narrative. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. TG Therapeutics Investment Narrative Recap To own TG Therapeutics, you need to believe BRIUMVI can remain the core growth engine while the company manages payer pressure, safety scrutiny, and intensifying MS competition. Completion of enrollment for the Phase 3 subcutaneous BRIUMVI trial directly affects the key near term catalyst: potential expansion into the self-administered segment. It may also partially offset the biggest current risk, which is the market shift and pricing pressure toward lower cost, at home therapies that could otherwise undercut the IV franchise. The most relevant recent announcement alongside this trial milestone is the Q4 2025 earnings report, showing BRIUMVI driven revenue of about US$616,287,000 for 2025 and positive net income. That financial performance underpins the consensus view that TG is now a profitable, BRIUMVI centric business, so any future readout from the subcutaneous Phase 3 program could meaningfully influence how durable that earnings base appears relative to both opportunity and risk. Yet beneath the excitement around subcutaneous BRIUMVI, investors should be